TABLE OF CONTENTS
1 INTRODUCTION 70
1.1 OBJECTIVES OF THE STUDY 70
1.2 MARKET DEFINITION 70
1.3 OVERVIEW OF THE NORTH AMERICA RADIOPHARMACEUTICALS MARKET 70
1.4 LIMITATIONS 72
1.5 MARKETS COVERED 72
2 MARKET SEGMENTATION 75
2.1 MARKETS COVERED 75
2.2 GEOGRAPHICAL SCOPE 76
2.3 YEARS CONSIDERED FOR THE STUDY 77
2.4 CURRENCY AND PRICING 77
2.5 DBMR TRIPOD DATA VALIDATION MODEL 78
2.6 MULTIVARIATE MODELLING 81
2.7 PRODUCT TYPE LIFELINE CURVE 81
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 82
2.9 DBMR MARKET POSITION GRID 83
2.10 MARKET TESTING TYPE COVERAGE GRID 85
2.11 VENDOR SHARE ANALYSIS 86
2.12 SECONDARY SOURCES 87
2.13 ASSUMPTIONS 87
3 EXECUTIVE SUMMARY 88
4 PREMIUM INSIGHTS 91
4.1 PESTEL ANALYSIS 92
4.2 PORTERS FIVE FORCES 93
4.3 PIPELINE ANALYSIS 94
4.4 PATENT ANALYSIS 95
4.5 DRUG TREATMENT RATE BY MATURED MARKETS 101
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 102
4.7 PATIENT FLOW DIAGRAM 103
4.8 KEY PRICING STRATEGIES 103
4.9 KEY PATIENT ENROLLMENT STRATEGIES 104
5 LIST OF CYCLOTRONS 106
5.1 NORTH AMERICA 106
6 REGULATORY SCENARIO 113
6.1 NORTH AMERICA 113
7 MARKET OVERVIEW 114
7.1 DRIVERS 116
7.1.1 THE GROWING DEMAND FOR RADIOPHARMACEUTICALS IN DIAGNOSTICS AND CLINICAL USE 116
7.1.2 THE INCREASING NEED FOR PHARMACEUTICAL PRODUCTS ACROSS VARIED THERAPEUTIC AREAS 116
7.1.3 THE INCREASING PREVALENCE OF CHRONIC DISEASES 117
7.2 RESTRAINTS 117
7.2.1 STRINGENT REGULATIONS FOR RADIOPHARMACEUTICALS 117
7.2.2 POTENTIAL RISKS ASSOCIATED WITH RADIOPHARMACEUTICALS 117
7.3 OPPORTUNITIES 118
7.3.1 THE RISING RESEARCH AND DEVELOPMENT EXPENDITURE OF RADIOPHARMACEUTICALS 118
7.3.2 THE GROWING INCIDENCES OF COMPLEX DISEASES IN GERIATRIC POPULATION 118
7.4 CHALLENGES 119
7.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS 119
7.4.2 LACK OF TECHNICAL EXPERTISE AND HIGH COST FOR TRAINING EXISTING WORKFORCE 120
8 NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY TYPE 121
8.1 OVERVIEW 122
8.2 DIAGNOSTIC RADIOPHARMACEUTICALS 125
8.2.1 PET RADIOPHARMACEUTICALS 126
8.2.1.1 F-18 126
8.2.1.2 RU-82 126
8.2.1.3 OTHER PET ISOTOPES RADIOPHARMACEUTICALS 126
8.2.2 SPECT RADIOPHARMACEUTICALS 127
8.2.2.1 TECHNETIUM-99M 127
8.2.2.2 GALLIUM-67 127
8.2.2.3 IODINE-123 127
8.2.2.4 THALLIUM-201 127
8.2.2.5 OTHER SPECT ISOTOPES 127
8.3 THERAPEUTIC RADIOPHARMACEUTICALS 128
8.3.1 BRACHYTHERAPY ISOTOPES 129
8.3.1.1 IODINE-125 129
8.3.1.2 PALLADIUM-103 129
8.3.1.3 CESIUM-131 129
8.3.1.4 IRIDIUM-192 130
8.3.1.5 OTHER BRACHYTHERAPY ISOTOPES 130
8.3.2 BETA EMITTERS 130
8.3.2.1 IODINE-131 130
8.3.2.2 LUTHETIUM-177 130
8.3.2.3 SAMARIUM-153 130
8.3.2.4 YTTRIUM-90 130
8.3.2.5 RHENIUM-186 131
8.3.2.6 OTHER BETA EMITTERS 131
8.3.3 ALPHA EMITTERS 131
8.3.3.1 RA-223 131
8.3.3.2 OTHERS 131
9 NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY APPLICATION 132
9.1 OVERVIEW 133
9.2 DIAGNOSTIC 136
9.2.1 PET 137
9.2.1.1 ONCOLOGY 137
9.2.1.2 CARDIOLOGY 137
9.2.1.3 NEUROLOGY 137
9.2.1.4 OTHER PET APPLICATION 137
9.2.2 SPECT 138
9.2.2.1 CARDIOLOGY 138
9.2.2.2 BONE SCANS 138
9.2.2.3 THYROID APPLICATIONS 138
9.2.2.4 PULMONARY SCANS 138
9.2.2.5 OTHER SPECT APPLICATION 138
9.3 THERAPEUTIC 139
9.3.1 THYROID INDICATIONS 140
9.3.2 BONE METASTASIS 140
9.3.3 LYMPHOMA 140
9.3.4 ENDOCRINE TUMORS 140
9.3.5 OTHER INDICATIONS 140
10 NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY SOURCE 141
10.1 OVERVIEW 142
10.2 NUCLEAR REACTORS 145
10.3 CYCLOTRONS 146
11 NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY END USER 147
11.1 OVERVIEW 148
11.2 HOSPITALS 151
11.3 DIAGNOSTIC CENTERS 151
11.4 CANCER RESEARCH INSTITUTES 152
11.5 AMBULATORY SURGICAL CENTERS 153
11.6 OTHERS 154
12 NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY REGION 155
12.1 NORTH AMERICA 156
12.1.1 U.S. 170
12.1.2 CANADA 179
12.1.3 MEXICO 188
13 NORTH AMERICA RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE 197
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 197
14 SWOT ANALYSIS 198
15 COMPANY PROFILE 199
15.1 CARDINAL HEALTH 199
15.1.1 COMPANY SNAPSHOT 199
15.1.2 REVENUE ANALYSIS 199
15.1.3 COMPANY SHARE ANALYSIS 200
15.1.4 PRODUCT PORTFOLIO 200
15.1.5 RECENT DEVELOPMENT 201
15.2 ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY 202
15.2.1 COMPANY SNAPSHOT 202
15.2.2 REVENUE ANALYSIS 202
15.2.3 COMPANY SHARE ANALYSIS 203
15.2.4 PRODUCT PORTFOLIO 203
15.2.5 RECENT DEVELOPMENT 203
15.3 LANTHEUS 204
15.3.1 COMPANY SNAPSHOT 204
15.3.2 REVENUE ANALYSIS 204
15.3.3 COMPANY SHARE ANALYSIS 205
15.3.4 PRODUCT PORTFOLIO 205
15.3.5 RECENT DEVELOPMENT 205
15.4 CURIUM 206
15.4.1 COMPANY SNAPSHOT 206
15.4.2 COMPANY SHARE ANALYSIS 206
15.4.3 PRODUCT PORTFOLIO 207
15.4.4 RECENT DEVELOPMENT 207
15.5 GENERAL ELECTRIC COMPANY 208
15.5.1 COMPANY SNAPSHOT 208
15.5.2 REVENUE ANALYSIS 208
15.5.3 COMPANY SHARE ANALYSIS 209
15.5.4 PRODUCT PORTFOLIO 209
15.5.5 RECENT DEVELOPMENT 209
15.6 BRACCO 210
15.6.1 COMPANY SNAPSHOT 210
15.6.2 PRODUCT PORTFOLIO 210
15.6.3 RECENT DEVELOPMENT 210
15.7 BWX TECHNOLOGIES. INC. 211
15.7.1 COMPANY SNAPSHOT 211
15.7.2 REVENUE ANALYSIS 211
15.7.3 PRODUCT PORTFOLIO 212
15.7.4 RECENT DEVELOPMENT 212
15.8 CHINA ISOTOPE & RADIATION CORPORATION 213
15.8.1 COMPANY SNAPSHOT 213
15.8.2 REVENUE ANALYSIS 213
15.8.3 PRODUCT PORTFOLIO 214
15.8.4 RECENT DEVELOPMENT 214
15.9 COQUI RADIOPHARMACEUTICALS CORP. 215
15.9.1 COMPANY SNAPSHOT 215
15.9.2 PRODUCT PORTFOLIO 215
15.9.3 RECENT DEVELOPMENT 215
15.10 ECKERT & ZIEGLER 216
15.10.1 COMPANY SNAPSHOT 216
15.10.2 REVENUE ANALYSIS 216
15.10.3 PRODUCT PORTFOLIO 217
15.10.4 RECENT DEVELOPMENT 217
15.11 ECZACIBAI-MONROL 218
15.11.1 COMPANY SNAPSHOT 218
15.11.2 PRODUCT PORTFOLIO 218
15.11.3 RECENT DEVELOPMENT 218
15.12 EVERGREEN THERAGNOSTICS, INC. 219
15.12.1 COMPANY SNAPSHOT 219
15.12.2 PRODUCT PORTFOLIO 219
15.12.3 RECENT DEVELOPMENT 219
15.13 NORTH AMERICA MEDICAL SOLUTIONS 220
15.13.1 COMPANY SNAPSHOT 220
15.13.2 PRODUCT PORTFOLIO 220
15.13.3 RECENT DEVELOPMENT 220
15.14 IBA WORLDWIDE 221
15.14.1 COMPANY SNAPSHOT 221
15.14.2 REVENUE ANALYSIS 221
15.14.3 PRODUCT PORTFOLIO 222
15.14.4 RECENT DEVELOPMENT 222
15.15 INSTITUTE OF ISOTOPES 223
15.15.1 COMPANY SNAPSHOT 223
15.15.2 PRODUCT PORTFOLIO 223
15.15.3 RECENT DEVELOPMENT 223
15.16 ISOTOPE JSC 224
15.16.1 COMPANY SNAPSHOT 224
15.16.2 PRODUCT PORTFOLIO 224
15.16.3 RECENT DEVELOPMENT 224
15.17 JUBILANT RADIOPHARMA A JUBILANT PHARMOVA COMPANY 225
15.17.1 COMPANY SNAPSHOT 225
15.17.2 REVENUE ANALYSIS 225
15.17.3 PRODUCT PORTFOLIO 226
15.17.4 RECENT DEVELOPMENT 226
15.18 NTP 227
15.18.1 COMPANY SNAPSHOT 227
15.18.2 PRODUCT PORTFOLIO 227
15.18.3 RECENT DEVELOPMENT 227
15.19 PHARMALOGIC HOLDINGS CORP 228
15.19.1 COMPANY SNAPSHOT 228
15.19.2 PRODUCT PORTFOLIO 228
15.19.3 RECENT DEVELOPMENT 228
15.20 SHINE TECHNOLOGIES, LLC 229
15.20.1 COMPANY SNAPSHOT 229
15.20.2 PRODUCT PORTFOLIO 229
15.20.3 RECENT DEVELOPMENT 229
15.21 SIEMENS HEALTHCARE GMBH 230
15.21.1 COMPANY SNAPSHOT 230
15.21.2 REVENUE ANALYSIS 230
15.21.3 PRODUCT PORTFOLIO 231
15.21.4 RECENT DEVELOPMENT 231
16 QUESTIONNAIRE 232
17 RELATED REPORTS 235

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.